A new antibiotic is effective against gonorrhea (gonorrhea). It has already been approved in the US and it is not yet available in Europe. In times of increasing antibiotic resistance, however, it can soon be a new option in the fight against venereal diseases.
An antibiotic approved in the United States for the treatment of urinary tract infections of women has used a drug against gonorrhea and previously used. This resulted in a study presented during the annual congress of the European Society for Clinical Microbiology and Infectious Diseases in Vienna (11 to 15 April). The active ingredient in tablet form is new.
The active ingredient of the drug is Potidacin. It is a so -called topoisomerase inhibitor that blocks an enzyme that is important for replication replication. Certain topoisomerase blockers have also been used for years in the treatment of tumor diseases.
Potidacin is likely to be available in the United States in the second half of 2025. There is still no approval in the EU of the Agency EMA.
Effectiveness also against Ripper
According to the British pharmaceutical company GSK, the drug is indicated against the antibiotic against the antibiotic companies such as Escherichia Coli, Citrobacter Freundii complex, Enterococcus Faecalis, Klebsiella pneumonia and Staphylococcus saprophia.
A total of 628 patients older than twelve years and a body weight of more than 45 kilograms were included in scientific research.
Success rate of more than 90 percent
The test subjects had confirmed a tripper infection by laboratory finding. Half was treated by chance with conventional therapy (500 milligrams of ceftriaxon as an intramuscular injection and a tablet of one gram of azithromycin) or received two tablets with Potidacin (each 300 milligram) for taking ten to twelve hours. According to the laboratory test, the elimination of gonorrhea was considered crucial for success within four to eight days. The data from 202, which had been treated with Potidacin and from 204 patients in the comparison group, could be evaluated. Since the gonorrhea is sexually transferred, it was ensured that there were comparable people with different sexual orientation in both groups (sex between men, heterosexual contacts).
The treatment results in both groups were de facto the same: with the two tablets of the new antibiotic, 92.6 percent of those treated with them could be cured. In the comparison group with the form of therapy so far (Cefriaxon and Azithromycin), the success rate was 91.2 percent. 92 percent of the subjects had been men.
Important new medication
“The authors explain that the new treatment could be an important instrument in combating the increase in gonorrhea tribes that become resistant to standard treatment,” emphasized the scientific journal. Moreover, treatment in tablet form would only make patient treatment more pleasant and easier for the health care system without injection.
Source: Krone
I am Wallace Jones, an experienced journalist. I specialize in writing for the world section of Today Times Live. With over a decade of experience, I have developed an eye for detail when it comes to reporting on local and global stories. My passion lies in uncovering the truth through my investigative skills and creating thought-provoking content that resonates with readers worldwide.
